Literature DB >> 19657703

Case report: psoriatic erythroderma with bilateral osseous bridge across the acetabulum.

Shigeyoshi Tsuji1, Tetsuya Tomita, Masahiro Inaoka, Mari Higashiyama.   

Abstract

Abnormal reactions accompanied by bone formation in the osteoarticular region induced by long-term administration of etretinate have been reported. We treated a patient who received continuous treatment of psoriatic erythroderma with etretinate for 7 years, and who had an osseous bridge that extended across the acetabulum over the femur on both sides. The patient experienced a major gait disturbance and eventually was unable to walk. Functional gait was restored by resecting the ossified regions and radiotherapy. Histologic sections of the ossified lesions showed enchondral ossification in the ligament attachment site in the joint margin, with advancing ossification along the articular capsule; the pattern was similar to that in diffuse idiopathic skeletal hyperostosis. This is the first report of an osseous bridge associated with long-term administration of etretinate extending across the acetabulum over the femur on both sides.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19657703      PMCID: PMC2835593          DOI: 10.1007/s11999-009-1010-8

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  11 in total

1.  Extraspinal tendon and ligament calcification associated with long-term therapy with etretinate.

Authors:  J J DiGiovanna; R K Helfgott; L H Gerber; G L Peck
Journal:  N Engl J Med       Date:  1986-11-06       Impact factor: 91.245

2.  Retrospective radiographic study of skeletal changes after long-term etretinate therapy.

Authors:  B Melnik; S Glück; R M Jungblut; G Goerz
Journal:  Br J Dermatol       Date:  1987-02       Impact factor: 9.302

3.  Diffuse hyperostosis associated with etretinate.

Authors:  S Burge; T Ryan
Journal:  Lancet       Date:  1985-08-17       Impact factor: 79.321

Review 4.  Lack of significant skeletal changes after long-term, low-dose retinoid therapy: case report and review of the literature.

Authors:  Caroline P Halverstam; Joshua Zeichner; Mark Lebwohl
Journal:  J Cutan Med Surg       Date:  2006 Nov-Dec       Impact factor: 2.092

Review 5.  Prolonged treatment with oral retinoids in adults: no influence on the frequency and severity of spinal abnormalities.

Authors:  R J Van Dooren-Greebe; J A Lemmens; T De Boo; N M Hangx; A L Kuijpers; P C Van de Kerkhof
Journal:  Br J Dermatol       Date:  1996-01       Impact factor: 9.302

6.  The non-osteogenic mouse pluripotent cell line, C3H10T1/2, is induced to differentiate into osteoblastic cells by recombinant human bone morphogenetic protein-2.

Authors:  T Katagiri; A Yamaguchi; T Ikeda; S Yoshiki; J M Wozney; V Rosen; E A Wang; H Tanaka; S Omura; T Suda
Journal:  Biochem Biophys Res Commun       Date:  1990-10-15       Impact factor: 3.575

7.  Early skeletal hyperostoses secondary to 13-cis-retinoic acid.

Authors:  D R Pennes; C N Ellis; K C Madison; J J Voorhees; W Martel
Journal:  AJR Am J Roentgenol       Date:  1984-05       Impact factor: 3.959

8.  [Skeletal alterations associated with long-term etretinate therapy].

Authors:  N Okada; M Higashiyama; S Morimoto; K Yoshikawa
Journal:  Nihon Hifuka Gakkai Zasshi       Date:  1991-04

9.  Retinoic acid-induced cartilage resorption: induction of specific changes in protein synthesis and inhibition by tunicamycin.

Authors:  A Kistler
Journal:  Differentiation       Date:  1982-05       Impact factor: 3.880

10.  Effects of retinoids in bone.

Authors:  R F Kilcoyne
Journal:  J Am Acad Dermatol       Date:  1988-07       Impact factor: 11.527

View more
  1 in total

Review 1.  Nutrition and Psoriasis.

Authors:  Naoko Kanda; Toshihiko Hoashi; Hidehisa Saeki
Journal:  Int J Mol Sci       Date:  2020-07-29       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.